Shore Capital Partners ("Shore" or "Shore Capital"), a Chicago-based private equity firm with offices in Nashville, today ...

H-D Feminine Health, announces it has initiated the first randomized, placebo-controlled, double-blinded Phase 3 clinical trial cleared to proceed by the U.S. Food and Drug Administration (FDA) to ...

Oric Pharmaceuticals’ previously announced plan to focus resources on its two most advanced oncology drugs comes with a sting in its tail—the therapeutic-resistance-focused biotech is laying off 20 | ...

Positive Phase 2 results for BX211 demonstrated >40% wound size reduction vs. placebo in diabetic foot osteomyelitis patients ...

First patient dosed with CUE-102 for recurrent glioblastoma multiforme (rGBM) at Dana-Farber Cancer Institute (DFCI) BOSTON, ...

Topline data for registrational Phase 2 trial of KYV-101 in stiff person syndrome (SPS) andBLA submission anticipated in 1H 2026 Registrational Phase 3 KYV-101 trial in myasthenia gravis (MG) to inclu ...

A new vaccine aimed at a common cancer gene mutation could help stop aggressive pancreatic cancers from coming back, a small ...

Key Takeaways from the Complicated Urinary Tract Infections Pipeline Report ...

FDA confirmed at a July 2025 Type B meeting and in the subsequent meeting minutes that eGFR slope is an acceptable surrogate endpoint for accelerated approval of rilparencel in patients with type 2 di ...

Discover six of the top psychedelic companies developing novel drugs to expand the treatment scope for mental health ...

As the dust settles on its successful takeover of Awakn Life Sciences, investors are starting to appreciate the potential of ...

Oric Pharmaceuticals logged a wider loss in its latest quarter and said it plans to reduce investment in its discovery research group, resulting in a 20% workforce reduction.